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SUMMARY
Objective: This study aimed to evaluate the body fat content of HIV patients accord-
ing to the duration of antiretroviral therapy use (DURARV), < 1 year and ≥ 1 year. 
Methods: Multiple linear regression was used to investigate the association between ul-
trasonographic variables of body fat compartments (BFCs) of the face, arm, subcutane-
ous and visceral abdomen, and the following explanatory variables: gender, age, BMI, 
and DURARV. Results: Of all patients (187), 102 of them with DURARV ≥ 1 year were 
suffering from HIV-related lipodystrophy (HIV-LD), diagnosed through clinical ques-
tionnaires. Those with DURARV < 1 year (n = 85, ≈ 46%) did not have HIV-LD. Regard-
ing the visceral compartment, the difference between those with DURARV ≥ 1 year and 
< 1 year was 11 mm of additional fat content in those with DURARV ≥ 1 year. Women 
had more fat than men in all peripheral BFCs, while men had 7.2 mm more visceral fat 
than women, on average. Conclusion: Ultrasonography is a method capable of measur-
ing the thickness of BFCs and is applicable to clinical practice to diagnose HIV-LD. 
Keywords: HIV-related lipodystrophy syndrome; highly active anti-retroviral therapy; 
cross-sectional studies; HIV infection.
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INTRODUCTION
The advent of highly active antiretroviral therapy 
(HAART) resulted in a substantial increase in survival and 
improved quality of life for patients living with AIDS1,2. 
However, these patients started to present chronic com-
plications such as, for example, lipodystrophy and diverse 
metabolism alterations3,4. 
HIV-related lipodystrophy (HIV-LD) involves disor-
ders of lipid metabolism and glucose and body fat redis-
tribution. A typical pattern of body fat redistribution is the 
loss of subcutaneous fat in the face, limbs, and buttocks, 
called lipoatrophy. Another commonly observed pat-
tern is dorsocervical and trunk fat accumulation, as well 
as increased abdominal visceral fat, called lipohypertro-
phy. The combination of the two patterns is called mixed 
lipodystrophy3,5.
The diagnosis of lipodystrophy in HIV patients is usu-
ally subjective, whether it is carried out by patient self-
assessment or clinical evaluation by the physician6,7. In 
order to meet the needs for an objective method capable 
of performing this assessment accurately and easily, sev-
eral imaging methods have been suggested. Computed to-
mography (CT), magnetic resonance imaging (MRI), and 
dual energy X-ray absorptiometry (DEXA) are the imag-
ing methods considered to be the gold standard8. How-
ever, their use increases the already high cost of treating 
the patient with HIV-LD8-10. In this context, ultrasound 
is a promising method, with lower cost and good patient 
acceptance, besides being an easily accessible, simple, and 
noninvasive method11.
This article analyzed the differences in the amount of 
fat in body fat compartments (face, arms, subcutaneous 
and visceral abdomen) analyzed through ultrasonography 
in HIV patients on antiretroviral therapy (HAART). 
METHODS
The study sample consisted of patients with HIV on an-
tiretroviral regimen using HAART12, in accordance with 
the guidelines of the Brazilian Ministry of Health, who did 
or did not present HIV-related lipodystrophy (HIV-LD). 
Eligible patients included those with recent use of HAART 
(<1 year) and who did not have HIV-LD, and those under 
treatment for a period of ≥ 1 year, with HIV-LD. All pa-
tients were older than 18 years and were recruited during 
their visits to the outpatient clinic of a public hospital in 
the city of Rio de Janeiro, between November 2006 and 
October 2009.
The selected patients completed a form that included 
their demographic, clinical, and therapeutic character-
istics. The information of interest were: age (in years), 
gender, presence or absence of signs/symptoms associ-
ated with HIV/AIDS and lipodystrophy; ongoing or prior 
treatments, which enabled the later establishment of the 
presence of AIDS-dening diseases in the previous 30 
days, according to the criteria of the Centers for Disease 
Control and Prevention (CDC)13; the presence or absence 
of HIV-LD according to the criteria of Lichtenstein et al.6; 
and the duration of antiretroviral therapy use (DURARV) 
(continuous variable). 
The variable DURARV was further categorized into 
≥ 1 year and < 1 year of antiretroviral therapy use. Weight 
(kg) and height (m) were measured, and the body mass in-
dex (BMI) (kg/m2) was calculated. The clinical and thera-
peutic data provided by the patients were carefully veried 
in their medical records. In case of discrepancy between 
the information provided by the patient and that in the 
medical records, the information in the latter was chosen 
as the reference information.
Using the questionnaires for the assessment of body 
fat compartments (BFCs), all patients performed a self-as-
sessment of their BFCs, followed by a medical evaluation 
of these same compartments  by a single physician blinded 
to the results of the patient self-assessment.The purpose 
was to differentiate body shape alterations in these assess-
ments, such as loss of subcutaneous fat in the face, limbs 
and buttocks, and fat increase in the trunk and abdomen6.
The diagnosis of HIV-LD followed the validated diag-
nostic criteria proposed by Lichtenstein et al.6, which rely 
on the presence of at least one immediately perceptible 
sign associated with a discrete sign (detected only by care-
ful examination) of alteration in the previously described 
body compartment; on the agreement between the medi-
cal assessment and that performed by the patients on the 
assessed BFCs; and on the absence of any sign of AIDS-de-
ning illness for at least 30 days prior to the consultation. 
Abdominal obesity was not considered a dening sign of 
HIV-LD.  
The patients, at the end of clinical and ultrasonograph-
ic assessments, were then divided in two groups: those 
with DURARV ≥ 1 year and presence of HIV-LD, and 
those with DURARV < 1 year and no HIV-LD.
The documents that summarized the physicians’ and 
the participants’ assessments were kept in a safe storage by 
the lead investigator and compared only aer all the ultra-
sound measurements had been completed.
ULTRASONOGRAPHY
The ultrasonographic measures (SA-8000 EX equipment, 
Medison CO. Ltd.) were performed by a single, experi-
enced operator. The ultrasonographist was blinded to the 
medical information of the assessed patients. Each of the 
body fat compartments studied (face, arm, abdominal 
subcutaneous and visceral) was measured twice, and the 
mean value of these measurements was recorded in the 
data form of each patient. The calibration of the ultra-
sound equipment had the following characteristics: frame 
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Figure 1 – Measurement of subcutaneous adipose thickness 
of the face. Cross-sectional plane (10MHz) of the most 
prominent part of the zygomatic bone, from the internal 
skin layer to the outer fascia of the facial musculature. 
S, skin; A, subcutaneous adipose tissue; FM, facial muscle; Z, 
zygomatic bone; M, maxillary bone.
Figure 2 – Measurement of the subcutaneous adipose 
thickness of the abdomen. Cross-sectional view (10MHz), 
from the internal skin layer to the outer surface of the 
rectus abdominis muscles. 
S, skin; A, adipose subcutaneous tissue; LA, linea alba; R, rectus 
abdominis; ABD, abdomen; U, above umbilicus.
average = 2, edge enhanced = 0, dynamic range = 105%, 
reject level = 2, view area = wide, tissue = normal, trap-
ezoid = off, apex = up, frame rate = fast, and power = 80. 
The mean time between the interview/clinical assessment 
and ultrasonographic measurements was three days. 
The measurements of fat thickness were performed us-
ing a high-frequency linear probe (10 MHz) lightly posi-
tioned transversely at a perpendicular angle to the body 
surface with the patient lying on the table in the supine 
position without a pillow. The probe was positioned on 
three anatomical landmarks, according to the description 
of the study by Martinez et al.11. On the malar region, the 
positioning was on the most prominent point of the zy-
gomatic bone (cheekbone). Facial fat thickness was mea-
sured from the inner layer of the skin to the external fascia 
of the supercial facial muscle, at the point of junction of 
the zygomatic and maxillary bones (Figure 1).  
In the brachial region, the mid-third of the right arm 
was placed in pronation and aligned with the body. Once 
the images of the humerus and the muscle had been dis-
played together on the screen, the image was frozen and 
the measurement of fat thickness was taken from the in-
ner layer of skin to the external fascia of the biceps. In the 
umbilical region, just above the umbilicus, fat thickness 
was measured from the inner layer of the skin to the up-
per surface of the rectus abdominis, in the middle of the 
linea alba, with the patient holding the breath (Figure 2). 
Visceral fat thickness was measured in the umbilical area 
with a low-frequency probe (3.5 MHz) positioned perpen-
dicularly and transversely to the body surface. Visceral fat 
measurement was performed from the inner surface (pos-
terior) of the rectus abdominis muscles to the posterior 
wall of the abdominal aorta, just above its bifurcation, in 
accordance with the study by Radominski et al.14.  
The study protocol was approved by the hospital eth-
ics committee and all patients signed the informed con-
sent for the ultrasonographic and clinical-epidemiological 
evaluation. 
STATISTICAL ANALYSIS 
Multiple linear regression was used to investigate the as-
sociation between the variables of the BFCs (face, arm, 
subcutaneous and visceral abdominal fat), measured by 
ultrasonography, and the following explanatory vari-
ables: gender, age, BMI, and time on antiretroviral therapy 
(DURARV ≥ 1 year and < 1 year). The assumptions of 
linear regression models were analyzed graphically and 
through statistical tests15. The normality and homoscedas-
ticity test results of the residues of each model are shown 
in Table 1. Statistical analysis was performed using the 
open source statistical package R, release 2.11.116.   
RESULTS
The study sample consisted of 187 patients, mean age 
(± standard error) of 42 (± 0.8) years, of which 137 
(≈ 73%) were males. The time of treatment showed a 
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BFC Face Arms Subcutaneous abdomen Visceral abdomen
Variables of 
interest
Univ. Multivar. Univ. Multivar. Univ. Multivar. Univ. Multivar.
BMI (0.16 ± 0.02)δ (0.2 ± 0.03)δ (0.22 ± 0.02)δ (0.2 ± 0.02)δ (1.2 ± 0.1)δ (1.2 ± 0.1)δ (1.9 ± 0.23)δ (2.4 ± 0.2)δ
DURARV  
(< 1 year)*
(0.8 ± 0.2)δ (0.7 ± 0.2)δ (0.42 ± 0.2)¥ (0.4 ± 0.16)δ (4.6 ± 1.3)α (4.4 ± 1.1)δ (-8.5 ± 1.9)δ (-11.2 ± 1.5)δ
Gender (F)§ (0.4 ± 0.2)α (0.7 ± 0.2)δ (1.7 ± 0.2)δ (1.9 ± 0.18 )δ (6.4 ± 1.4)δ (7.7 ± 1.2)δ (-7.2 ± 2.2)α (17.4 ± 9.8)¥
BMI: gender§§ – – – – – – – (-1.1 ± 0.4)δ
r2 // – 0.25 – 0.56 – 0.41 – 0.5
Liberty grades – 184 – 184 – 184 – 183
Normality 
test#
– 0.051 – 0.1 – 0.1 – 0.3
Homog. T. 
Var.**
– 0.06 – 0.2 – 0.1 – 0.7
BMI, body mass index (continuous variable); *duration of antiretroviral therapy use with exposure category < 1 year; §exposure category: female gender; 
§§interaction term between BMI and gender; //quality adjustment of the linear model; #p-value of the Kolmogorov-Smirnov test for normality; **p-value of Bartlett 
test of homogeneity of variances; Univ., univariate estimation of the model; Multivar., multivariate estimation of the model ± standard deviation; BFC, body fat 
compartments; δ< 0.01; α< 0.05; ¥< 0.10.
Table 1 – Linear models of body fat compartments
bimodal distribution, and a cutoff was set at one year. In 
the group of patients with more than 1 year of treatment 
(n = 85, ≈ 46%) the mean time was 3,418 (± 139) days of 
treatment. All these patients had HIV-LD. In patients with 
< 1 year of antiretroviral drug use (n = 102), the average 
time of treatment was 73 (± 7.2) days and there were no 
cases of HIV-LD. The signicant difference in time be-
tween the treatment groups (t = 24, p < 0.0001) and the in-
terval of 475 days between the extremes of the two groups 
justies the dichotomization of this variable used in the 
multivariate analysis. 
The mean ultrasonographic measurements of the BFCs 
of face, arm, subcutaneous and visceral abdomen were re-
spectively 3.43 (± 0.1) mm, 1.8 (± 0.13) mm, 13.4 (± 0.7), 
and 45.5 mm (± 1) mm for all patients. The univariate re-
gression coe cients of the variables of interest (age, BMI, 
DURARV, and gender) and their signicance values  are 
shown in Table 1. The mean BMI of the study population 
was 24.4 kg/m2 (± 0.28). There was no association between 
BMI and gender (males: 24.5 (± 0.30) kg/m2); females: 
24.1 (± 0.62) kg/m2, t = 0.76, p = 0.5), or between BMI 
and treatment duration (group > 1 year: 24 (± 0.5) kg/m2; 
group < 1 year: 25 (± 0.3) kg/m2); t = -1.713, p = 0.9). On 
the other hand, patients with DURARV > 1 year were 
signicantly older (49 (± 1)) than those with DURARV 
< 1 year (age 37 (± 0.9), t = 8.8, p < 0.0001). 
In multivariate analysis, the variables BMI, gender, and 
time of treatment were signicantly associated with all 
BFC measurements analyzed by ultrasound.
Females had 0.7 mm, 1.9 mm and 7.7 mm more fat, 
respectively, in the face, neck, and subcutaneous abdomen, 
on average, than the corresponding values of the respec-
tive male compartments. As for the male visceral compart-
ment, there was an increase of 7.2 mm in fat compared 
to the same compartment in females. The increase of one 
unit of BMI was associated with increased fat in all BFCs 
studied, and ranged from 0.2 mm in the face and arm to 
1.2 mm and 2.4 mm in the subcutaneous and visceral ab-
domen, respectively.  
The thickness of body fat compartments was strongly 
associated with treatment time in both men and women. 
In those with DURARV < 1 year there was, respectively, an 
increase of fat of 0.4 mm and 0.7 mm, in the arm and face, 
and 4.4 mm in the subcutaneous abdominal compart-
ment (Table 1). Conversely, in the visceral compartment, 
patients with DURARV ≥ 1 year had on average 11 mm 
more visceral fat than patients with shorter treatment time 
(Table 1).  
DISCUSSION
It has been estimated that by the end of 2009 there were 
approximately 35 million people living with HIV world-
wide; of these, more than 95% were living in countries 
with low and middle incomes. In these countries there are 
now approximately 5.2 million people using antiretroviral 
medications, and 10 million people awaiting the expan-
sion of antiretroviral therapy programs in order to start 
treatment17. 
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The Ministry of Health reported 592,914 cases of AIDS 
(clinical syndrome) in Brazil, from 1980 until June 201018; 
of these, 200,000 regularly receive antiretroviral treat-
ment19. In spite of the substantial increases in the quality 
and length of survival of HIV patients since its ãrst use in 
1996, this type of therapy has signiãcant adverse effects20, 
in addition to the diã culties of treatment compliance in 
the long term, which, so far, corresponds to a period that 
encompasses the life of each patient with HIV/AIDS21. 
The prevalence of abnormal fat redistribution in differ-
ent studies is closely associated with the duration of anti-
retroviral use, and other factors such as age, gender, body 
weight, and duration of HIV infection. Except for the last 
variable, of which information is inaccurate or unknown 
for most people with HIV, the others were studied in the 
present study, as well as in other international studies3,7,8, 
by regression models of fat compartments of interest. 
The gender of patients has a signiãcant effect on 
changes in body composition of fat that occur during HIV 
infection; women, who usually have a higher proportion 
of fat mass when compared to men, lose disproportion-
ately more fat, thus reducing the sexual differences in body 
composition of HIV patients over time22. Kotler et al.22 also 
observed that the amounts of fat in subcutaneous com-
partments are higher among women, when compared to 
men. The opposite is observed with respect to the visceral 
compartment: there is a smaller amount of fat in women 
when compared to men, and these observations were cor-
roborated by the present study. 
Height and weight have a strong inãuence on the mass 
of body cells, in relation to both lean mass and fat mass22. 
As expected, a positive association between BMI and fat 
content of body compartments, particularly in the visceral 
compartment, was found. Conversely, there was no statis-
tically signiãcant association between BMI and length of 
use of antiretrovirals. This result suggests that the fat loss 
occurs in the same amounts in patients with different BMI 
values. In turn, the impact of this loss, when measured as 
loss relative to the initial weight, will be greater in those 
with lower BMI, as the loss of fat mass will be signiãcantly 
higher in relation to the pre-existing fat mass. 
The smaller amounts of fat measured in the peripheral 
compartments of patients with DURARV ≥ 1 year/HIV-LD 
compared with those with DURARV < 1 year/without 
HIV-LD, suggest a thinning of the arm and fat atrophy in 
the face and abdomen, possibly in response to treatment. 
In the latter (the stomach compartment compressible with 
the ãngers), which is not normally measured by the clinical 
diagnostic methods of HIV-LD5,23, there was a substantial 
reduction of fat associated with longer time of treatment.   
Regarding the visceral compartment, there was a great-
er amount of fat in the group receiving prolonged treat-
ment (> 1 year), compared to the group that had started 
treatment more recently (< 1). The visceral fat accumula-
tion usually occurs in the clinical pictures of abnormal fat 
redistribution, but its presence alone does not deãne the 
diagnosis of HIV-LD, as there are other diseases or disor-
ders that also course with visceral obesity, such as meta-
bolic syndrome. Therefore, it is necessary to perform dif-
ferential diagnosis before associating visceral obesity with 
HIV-LD.  
In routine care, the diagnosis of HIV-LD is per-
formed based on the self-assessment of patients and on 
the attending physician’s assessment (subjective informa-
tion), due to the considerable advantages, such as low 
cost and ãexibility of the language used in the question-
naire, adjusted to the patient’s language skills. This diag-
nostic method was validated by Lichtenstein6, who, in a 
multicenter U.S. study, evaluated 1,077 patients with HIV 
submitted to self-assessment and evaluation by their phy-
sicians for signs of HIV-LD. Patients who had diagnostic 
concordance of HIV-LD in both evaluations were con-
sidered as having HIV-LD.
In a study of objective deãnition of lipodystrophy, in 
which 10 clinical and metabolic variables were used, and 
the variables related to body compartments were measured 
by DEXA, the authors24 showed a sensitivity of 79% and a 
speciãcity of 80% for the diagnosis of HIV-LD. However, 
this method is currently restricted to health facilities with 
better infrastructure, as it relies on sophisticated metabolic 
tests and DEXA, which are not on the list of routine ex-
aminations in most Brazilian hospitals. Ultrasound may 
represent an intermediate option between the high-tech 
methods, which have higher cost and lower availability in 
medical facilities, and methods based on subjective infor-
mation only, which have lower cost and are widely avail-
able, but also generally show problems with accuracy, reli-
ability, and validity8. 
Sectional studies with HIV patients, conducted in 
Spain25,26, assessed the inter-exam reliability of ultrasound, 
CT, and DEXA, when evaluating fat compartments in the 
subcutaneous abdomen and arm in patients with lipoatro-
phy, and found statistically signiãcant correlations25,26. In 
the arm, the Spearman’s rank correlation coeã cient var-
ied from 0.64 to 0.84, whereas in the subcutaneous abdo-
men, these correlations, although weak, were statistically 
signiãcant, and ranged from 0.34 (p-value < 0.05) to 0.40 
(p = 0.001)25,26. Similarly, for the visceral fat, a good repro-
ducibility of ultrasound measurements when compared 
with CT (r = 0.84) was observed26.  
In another study, which measured visceral fat thickness 
by ultrasound in patients with HIV receiving antiretroviral 
therapy versus those who had never received it, Guimarães 
et al.27 also found differences in visceral adiposity that 
were signiãcantly higher in the group of patients receiving 
antiretrovirals. 
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Most studies of inter-exam reliability that evaluated the 
ultrasonography for the face and clinical methods found a 
signicant correlation between them11,28,29. However, Carey 
et al.30 found no signicant association between the malar 
region studied by ultrasound and other body regions stud-
ied by different methods of measurement, such as CT and 
DEXA. It can be postulated that it would not be possible 
to establish correlation between the measurements, as the 
method used in this study did not maintain similar ob-
servation conditions in the several procedures performed. 
An additional advantage of ultrasonography is the 
low variability of its measurements of subcutaneous 
(< 5%)11,27,31 and visceral (2.6%) fat thickness when per-
formed by a single well-trained operator.
The multivariate model adjusted for ultrasonographic 
data of the face had the worst quality of t (r2 = 0.25). Two 
possible explanations can be proposed. First, this result 
suggests the need to include in these evaluations additional 
variables that were not studied in the present study. How-
ever, no studies in the literature that used linear regression 
to study the differences in body fat compartments in this 
population were found, so it is not possible to compare the 
present results with those of other studies. 
The fact that the measurement of facial fat has the 
highest degree of technical di culty among the proce-
dures used in this study is noteworthy. Anatomical varia-
tions and variability in facial shape and fat content of this 
body compartment require the ultrasonographist’s skill to 
produce an image that includes the anatomical reference 
points (the junction of the zygomatic and maxillary bones 
in the lower right eye socket, and adjacent muscle and fat 
tissues) (Figure 1). Therefore, one possible explanation for 
the high variability observed in measurements of the face 
(and consequent low quality of t) would be the result of 
signicant differences in the form and content of the fat 
compartments of patients examined by ultrasound.
Simultaneously with the expansion of antiretroviral 
treatment provided to millions of HIV patients, there is 
ongoing development of new drugs with less toxic pro-
les, tending to replace rst and second-line antiretrovi-
ral drugs, which are relatively inexpensive, effective, and 
widely prescribed, but are oen associated with metabolic 
disorders and HIV-LD. The economic impact of these sub-
stitutions in antiretroviral programs with free and univer-
sal access is likely to jeopardize the continued expansion of 
these programs for new patients and even the maintenance 
of those already being treated32. 
It is suggested that ultrasonography should be used to 
study the fat compartments, in parallel or in series with 
the clinical method of diagnosis of HIV-LD through-
out outpatient-based treatment. This approach is similar 
to that which has been routinely used in relation to the 
monitoring of immunological and metabolic parameters 
of patients in follow-up care. It is expected that ultrasound 
can be used as an important tool in early diagnosis of ab-
normal fat redistribution, and can indicate patients for 
whom replacement of antiretroviral drugs closely associ-
ated with HIV-LD by others with less pronounced side ef-
fects is recommended.
REFERENCES
1. Signorini DJHP, Codeço CT, Carvalho MS, Campos DP, Monteiro MCM, 
Andrade MFC, et al. Effect of sociodemographic, clinical-prophylactic and 
therapeutic procedures on survival of AIDS patients assisted in a Brazilian 
outpatient clinic. Rev Bras Epidemiol. 2005;8(3)253-61.
2. Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, Ganesan A, 
et al. Outcomes of highly active antiretroviral therapy in the context of univer-
sal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res 
Ther. 2010;7(1):14.
3. Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, Cinagawa E, et al. 
Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation 
with metabolic syndrome and cardiovascular risk factors. Arq Bras Endocrinol 
Metab. 2008;52(4):658-67.
4. Signorini DJ, Monteiro MC, Signorini DH, Eyer-Silva WA. Prevalence and de-
terminant factors to lipid abnormalities among HIV-infected patients: a cross-
sectional study of 812 patients. Arq Bras Endocrinol Metabol. 2010;54(6):583.
5. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-per-
ception of body changes in persons living with HIV/AIDS: prevalence and as-
sociated factors. AIDS. 2005;19(Suppl 4):S14-21.
6. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, 
et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory 
population. AIDS. 2001;15(11):1389-98.
7. Gelenske T, Bandeira EFFA, Alencar Ximenes RA, Lacerda de Melo HR, Mili-
tao de Albuquerque MD, Carvalho EH, et al. Risk factors in human immuno-
deç ciency virus/acquired immunodeç ciency syndrome patients undergoing 
antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study. 
Metab Syndr Relat Disord. 2010;8(3):271-7.
8. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with 
HIV infection. AIDS.1999;13(18):2493-505.
9. Huang JS, Becerra K, Fernandez S, Lee D, Mathews WC. The impact of HIV-
associated lipodystrophy on healthcare utilization and costs. AIDS Res Ther. 
2008;5:14.
10. Associação Médica Brasileira, aSdE, Conselho Federal de Medicina, Federação 
Nacional dos Médicos.  Classiç cação Brasileira Hierarquizada de Procedimen-
tos Médicos (CBHPM).  São Paulo; 2010. [cited 2011]. Available from: http://
www.amb.org.br/teste/cbhpm/cbhpm_2010.pdf.
11. Martinez E, Bianchi L, Garcia-Viejo MA, Bru C, Gatell JM. Sonographic assess-
ment of regional fat in HIV-1-infected people. Lancet. 2000;356(9239):1412-3.
12. Brasil. Recomendações para terapia antirretroviral em adultos infectados pelo 
HIV, 2008. [cited 2011 feb 2]. Available from: http://www.aids.gov.br/sites/de-
fault/ç les/consensoAdulto005c_2008montado.pdf.
13. Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan MD, et 
al. Division of HIV/AIDS Prevention Surveillance and Epidemiology. Surveil-
lance for AIDS-deç ning opportunistic illnesses, 1992-1997. Available from: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00056917.htm.
14. Radominski RB, Vezozzo DP, Cerri GG, Halpern A. O uso da ultrassonogra-
ç a na avaliação da distribuição de gordura abdominal. Arq Bras Endocrinol 
Metab. 2000;44(1):5-12.
15. Dalgaard P. Introductory statistics with R. New York: Springer; 2002.
16. Team RDC. R: a language and environment for statistical computing. 2.11. Vi-
enna: R Foundation for Statistical Computing; 2011.
17. UNAIDS/WHO. Joint United Nations Programme on HIV/AIDS WHO. UN-
AIDS report on the global AIDS epidemic 2010. 2010.
18. Boletim Epidemiológico Aids. DST (Versão Preliminar).  Brasília (DF); 2010. 
[cited 2011 feb 2]. Available from: http://www.aids.gov.br/sites/default/ç les/
publicacao/2010/boletim2010_preliminar_pdf_34434.pdf.
19. Ministério da Saúde. DST. AIDS hepatites virais.  Brasília (DF): Ministério da 
Saúde; 2011. [cited 2011 feb 4]. Available from: http://www.aids.gov.br/pagina/
quais-sao-os-antirretrovirais.
20. Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: lipodystrophy 
associated with HIV-1 infection and antiretroviral treatment. Biochim Bio-
phys Acta. 2010;1801(3):392-9.
21. Monnerat BZ, Cerutti Junior C, Canicali SC, Motta TR. Clinical and biochemi-
cal evaluation of HIV-related lipodystrophy in an ambulatory population from 
the Hospital Universitario Cassiano Antonio de Morais, Vitoria, ES, Brazil. 
Braz J Infect Dis. 2008;12(4):364-8.
22. Kotler DP, Thea DM, Heo M, Allison DB, Engelson ES, Wang J, et al. Relative 
inçuences of sex, race, environment, and HIV infection on body composition 
in adults. Am J Clin Nutr. 1999;69(3):432-9.
DIFFERENCES IN BODY FAT DISTRIBUTION ASSESSED BY ULTRASONOGRAPHY IN PATIENTS RECEIVING ANTIRETROVIRAL DRUGS
203Rev Assoc Med Bras 2011; 58(2):197-203
23. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of 
fat redistribution and metabolic change in HIV infection (FRAM): methods, 
design, and sample characteristics. Am J Epidemiol. 2006;163(9):860-9.
24. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective 
case deffnition of lipodystrophy in HIV-infected adults: a case-control study. 
Lancet. 2003;361(9359):726-35.
25. Martinez E, Milinkovic A, Bianchi L, Gatell JM. Considerations about 
the value of sonography for the measurement of regional body fat. AIDS. 
2006;20(3):465-6.
26. Padilla S, Gallego JA, Masia M, Ardoy F, Hernandez I, Gutierrez F. Ultraso-
nography and anthropometry for measuring regional body fat in HIV-infected 
patients. Current HIV Res. 2007;5(5):459-66.
27. Guimarães MM, Oliveira AR Jr, Penido MG, Queiroz LC, Goulart EM, Greco 
DB, et al. Ultrasonographic measurement of intra-abdominal fat thickness in 
HIV-infected patients treated or not with antiretroviral drugs and its correla-
tion to lipid and glycemic proffles. Ann Nutr Metab. 2007;51(1):35-41.
28. Asensi V, Martin-Roces E, Carton J, Collazos J, Maradona J, Alonso A, et al. 
Perirenal fat diameter measured by echography could be an early predictor of 
lipodystrophy in HIV type 1-infected patients receiving highly active antiret-
roviral therapy. Clin Infect Dis. 2004;39(2):240-7.
29. Gulizia R, Vercelli A, Gervasoni C, Ortu M, Calliada F, Troia G, et al. Con-
troversy concerning role of ultrasonographic lipoatrophy assessments in HIV 
patients. AIDS. 2006;20(5):789-90.
30. Carey D, Wand H, Martin A, Rothwell S, Emery S, Cooper DA, et al. Evalua-
tion of ultrasound for assessing facial lipoatrophy in a randomized, placebo-
controlled trial. AIDS. 2005;19(12):1325-7.
31. Asensi V, Martin-Roces E, Collazos J, Carton JA, Maradona JA, Alonso A, et al. 
Association between physical and echographic fat thickness assessments and a 
lipodystrophy grading scale in lipodystrophic HIV patients: practical implica-
tions. AIDS Res Hum Retroviruses. 2006;22(9):830-6.
32. Nunn AS, da Fonseca EM, Bastos FI, Gruskin S. AIDS treatment in Brazil: 
impacts and challenges. Health Aff (Millwood). 2009;28(4):1103-13.
